Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes aim at blood sugar in diabetes

NCT ID NCT01035879

Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing an experimental oral drug called MBX-2982 in adults with type 2 diabetes. The trial compares three daily doses of MBX-2982 against a placebo and sitagliptin, a standard diabetes drug, over four weeks. Participants are treatment-naive or taking a single oral diabetes medication. The main goal is to see how much the drug lowers blood sugar levels after meals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental oral drug called MBX-2982
What this could lead to
If it works, MBX-2982 could become another oral option for lowering blood sugar in people with type 2 diabetes.
What could go wrong
This is a small, short Phase 2 trial, so any blood sugar improvements may not last or may not hold up in larger studies. MBX-2982 may cause side effects or fail to beat existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Start date

Dec 2009

Finished

Aug 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of type 2 diabetes of at least 3 months duration * Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone) * HbA1c 7.0-8.5% (inclusive) at screening * BMI ≥ 26 kg/m2 for patients recruited from U.S or Georgia or ≥ 22 kg/m2 for patients recruited from India Exclusion Criteria: * Any history of type 1 diabetes or diabetic ketoacidosis * History of major upper GI surgery * Evidence or history of clinically significant GI illness including dyspepsia, PUD, nausea, diarrhea, malabsorption, etc. * History of outpatient insulin use within last 1 year (insulin use while hospitalized is acceptable) * Weight loss \> 10 pounds (4.5 kg) in the 3 months prior to screening visit or use of weight loss medications (prescription or OTC) within 30 days of screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • Bangalore Endocrinology & Diabetes Research Centre

    Malleshwaram, 560 003, India

  • Bharti Research Institute of Diabetes and Endocrinology

    Karnāl, Haryana, 132001, India

  • Diabetes Thyroid Hormone Research Institute Pvt Ltd

    Indore, M.P., 452001, India

  • Gandhi Endocrinology & Diabetes Centre

    Rāmdaspeth, Nagpur, 10, India

  • Georgian Diabetes Center

    Tbilisi, 0159, Georgia

  • Gokula Metropolis Research, MS Ramaiah Memorial Hospital

    Bangalore, 560 054, India

  • Healthy Life Clinical Diagnostic Center

    Tbilisi, 0144, Georgia

  • Hormone Care Research Centre

    Ghaziabad, 201002, India

  • Impact Clinical Trials

    Los Angeles, California, 90036, United States

  • Medisys Clinisearch India Pvt Ltd

    Bangalore, 560043, India

  • Medulla Chemotherapy and Immunotherapy Clinic

    Tbilisi, 0186, Georgia

  • Nevada Alliance Against Diabetes

    Las Vegas, Nevada, 89101, United States

  • United Medical Associates

    Binghamton, New York, 13901, United States

  • dgd Research, Inc., a Cetero Research Co.

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.